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1. Introduction 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B cell 
hyperactivity and defective T-cell function, with production of high titer autoantibodies and 
clinical involvement in multiple organ systems. Patients with mild SLE can generally be 
maintained on a combination of non-steroidal anti-inflammatory drugs and antimalarials. 
Corticosteroids, azathioprine and cyclophosphamide remain important for long term 
management of most patients with active disease and even those in clinical remission. 
However, these agents have considerable side effects and are not effective in all patients 
with SLE. Novel immunological therapies include both B and T cell directed treatments, 
anticytokine and complement directed therapies. These modalities enable more specific 
immunosuppression, and include cyclosporin, high-dose intravenous immunoglobulin, 
mycophenolate mofetil, tacrolimus and new purine nucleoside analogs (Schröder and 
Zeunerorts 2009).  
In recent years, clinical studies have been undertaken with selected monoclonal antibodies 
(mAbs) in the treatment of several hematological diseases, especially in malignant disorders. 
However, some clinical observations indicate that mAbs may be an important alternative for 
the conventional therapy of some autoimmune disorders (Robak 2004). 
B-lymphocytes are an essential component of the acquired immune response (La Cava 
2010). They randomly express cell-surface receptors which are often autoreactive and must 
be controlled by the process of B-cell tolerance. In SLE, the number of B-cells in the 
peripheral blood is often decreased, and those that are present have abnormal phenotypes 
indicative of activation. The important role of B cells in the pathogenesis of SLE has 
provided a strong rationale to target B cells in SLE. Selective therapeutic depletion of B-cells 
became possible with the availability of the anti-CD20 antibody rituximab.  
2. Anti-CD20 monoclonal antibodies 
The CD20 (B1) antigen is a 33–35 kDa integral membrane protein expressed on the surfaces 
of non-malignant and most malignant B cells (Cragg, Walshe et al. 2005). The CD20 protein 
consists of cytoplasmic N- and C-termini and four hydrophobic regions for anchoring the 
molecule in the membrane (Robak 2008). The characteristics that make CD20 a good target 
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antigen include its relatively high level of expression and close location of the extracellular 
epitopes to the cell surface. The intensity of antigen expression or the number of receptor 
sites on the cell surface appears to correlate with the clinical response. The cytotoxic activity 
of mAbs directed against CD20+ cells is thought to be based on antibody-dependent cellular 
cytotoxicity (ADCC) via natural killer (NK) cell responses, complement-dependent 
cytotoxicity (CDC), or by the induction of cell signaling followed by apoptosis. At present, 
rituximab is the most important mAb of clinical value in patients with autoimmune 
disorders and B-cell lymphoid malignancies. Over the last few years, new generations of 
anti-CD20 mAbs have been developed for potential benefits over rituximab (Robak and 
Robak 2011; Lim, Beers et al. 2010). They were engineered to have augmented antitumor 
activity by increasing CDC or ADCC activity and increased Fc binding affinity for the low-
affinity variants of the FcγRIIIa receptor (CD16) on immune effector cells. The second-
generation mAbs are humanized or fully human to reduce immunogenicity, but with an 
unmodified Fc region. They include ofatumumab, veltuzumab, and ocrelizumab. The third-
generation mAbs are also humanized but in comparison with the second-generation mAbs 
they also have an engineered Fc region designed to increase their effector functions by 
increasing binding affinity for the FcγRIIIa receptor (Ruuls, Lammerts et al. 2008). Both 
polymorphisms in FcγRIIIa and structure of mAb Fc can impact on the affinity between 
FcγRIIIa and mAb. The third-generation mAbs include AME133v, Pro13192, and GA-101. 
2.1 Rituximab 
Rituximab is an IgG-1 immunoglobulin, containing murine light– and heavy–chain 
variable–region sequences and human constant region sequences. Rituximab is known as 
the first-generation mAb. Since approval in 1997, rituximab has become the standard of care 
in follicular B-cell lymphomas (FL), CLL, and aggressive lymphomas when combined with 
chemotherapy (Hauptrock and Hess 2008). Rituximab is administered as an intravenous 
infusion with a recommended dosage of 375 mg/m2 given once weekly for 4 weeks. 
Treatment with this agent is usually well tolerated. However, infusion-related reactions 
occur in the majority of patients. These adverse events are typically fever, chills, rigors and 
rare hypotension and bronchospasm, although the incidence of these side effects decreases 
with subsequent rituximab infusion. Moreover, prolonged impairment of antibody 
production causes the increased risk of viral and bacterial infections. It should be also 
remembered that rituximab is a human mouse chimeric antibody and hence treated patients 
may be susceptible to the development of human antichimeric antibodies, which can impact 
on responsiveness.  
A recent study has shown that treatment with rituximab affects both the cellular and 
humoral arm of the immune system in patients with SLE (Lu, Ng et al. 2009).  
A number of prospective studies and several retrospective cohort studies of rituximab in the 
treatment of SLE have been reported (Cambridge, Isenbergetal. 2008). In 2005 Leonardo et 
al. (Leandro, Cambridge et al. 2005) described female patients with SLE who were treated 
with combination of rituximab, CY and prednisolone. Each patient received two infusions of 
rituximab (500 mg/dose), two infusions of cyclophosphamide (750 mg/dose) and 60 mg 
prednisolone per day for five days. Five patients were analyzed and one patient was lost to 
follow up after 3 months. All five patients showed an improvement in British Isles Lupus 
Assessment Group (BILAG) scores from a median of 14 at baseline to a median of 6 at six 
months. Recently, the same group reported the results of 46 patients with active SLE were 
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treated with a 1 gm of rituximab, 750 mg of cyclophosphamide, and 100-250 mg of 
methylprednisolone, administered on 2 occasions 2 weeks apart (Lu, Ng et al. 2009). Twenty 
one patients (47%) reached partial remission after one cycle (mean followup 39.6 months). 
Treatment resulted in a decrease in median global BILAG scores from 12 to 5 (P < 0.0001) 
and median anti-double-stranded DNA antibody titers from 106 to 42 IU/ml (P < 0.0001). In 
addition an increase in the median C3 level from 0.81 to 0.95 mg/liter (P < 0.02) at 6 months 
was observed. Five serious adverse events were noted.  
Willems et al. (Willems, Haddad et al. 2006) described the safety and efficacy of rituximab in 
11 girls (mean age 13.9 years) with severe SLE including 8 girls with class IV or V lupus 
nephritis, 2 girls with severe autoimmune cytopenia and 1 girl with an antiprothrombin 
antibody. Patients received 2 to 12 intravenous infusions of rituximab (350-450 mg/m2/ 
infusion) with corticosteroids. Remission was achieved in 6 of 8 patients with lupus 
nephritis and in two patients with autoimmune cytopenia. However, severe adverse events 
occurred in 45% of the patients in this study. 
Looney et al. reported the results of the first dose escalation study of rituximab for the 
treatment of SLE (Looney, Anolik et al. 2004). The drug was added to ongoing therapy in 18 
patients with moderately active SLE. Six patients received a single infusion of 100 mg/m2, 
six received one infusion of 375 mg/m2 and six patients received four weekly doses of 375 
mg/m2. In this study, rituximab-induced B cell depletion was translated into a significant 
improvement in SLE disease activity even in the absence of substantial serologic responses. 
Most patients were able to decrease corticosteroid dose from 13 to 10 mg by the end of the 
study and three patients were able to discontinue concomitant immunosuppressives. The 
clinical response was most notable for rashes and arthritis. 
Terrier et al. analyzed recently prospective data from the French AutoImmunity and 
Rituximab (AIR) registry, which includes data on patients with autoimmune disorders 
treated with rituximb (Terrier, Amoura et al. 2010). Overall response was observed in 80 of 
113 patients (71%) by the SELENA-SLEDAI (SLE Disease Activity Index Score assessment). 
Efficacy was similar between patients receiving rituximab monotherapy and those receiving 
concomitant immunosuppressive agents. Articular, cutaneous, renal, and hematologic 
improvements were noted in 72%, 70%, 74%, and 88% of patients, respectively. In relapsed 
patients response was observed in 91% after retreatment with rituximab. Severe infections 
were observed in 12 patients (9%), corresponding to a rate of 6.6/100 patient-years. Most 
severe infections occurred within the first 3 months after the last rituximab infusion. Five 
patients died, due to severe infection (n = 3) or refractory autoimmune disease (n = 2). 
Merrill et al reported the results of the Exploratory Phase II/III SLE Evaluation of Rituximab 
(EXPLORER) trial, a placebo-controlled, double-blind, multicenter study of rituximab in 
patients with moderately-to-severely active extrarenal SLE (Merrill, Neuwelt et al. 2010). 
Patients were randomized at a 2:1 ratio to receive intravenous rituximab (1,000-mg) or 
placebo on days 1, 15, 168, and 182, which was added to prednisone. Of the 257 patients, 88 
were assigned to receive placebo, and 169 were randomized to the rituximab arm. At week 
52, no difference was observed in major clinical responses or partial clinical responses 
between the placebo group. Decreases in the level of anti-dsDNA autoantibodies and 
increases in complement C3 and C4 levels were greater in the rituximab group than in the 
placebo group. The overall response rate was 28.4% and 29.6%, respectively. The proportion 
of patients in whom serious infection developed was 17% in the placebo group and 9.5% in 
the rituximab group. 
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Rituximab is also an active treatment agent in patients with lupus nephritis and central 
nervous system (CNS) involvement. Sfikakis et al. reported clinical response in 80% and 
sustained complete response in 40% of patients with class III and IV nephritis treated with 
rituximab and moderate doses of corticosteroids (Sfikakis, Boletis et al. 2005). In the study of 
Ng et al. 21 patients with renal involvement were treated with rituximab and 
cyclophosphamide (Ng, Cambridge et al. 2007). They had a decrease in median urinary 
protein creatinine ratio (PCR) from 446 to 190 mg/mmol 6 months. More recently, Pepper et 
al. treated 18 patients with class III/IV/V lupus nephritis with rituximab. All patients were 
on steroids prior to the development of lupus nephritis (Pepper, Griffith et al. 2009). The 
patients received mycophenolate mofetil maintenance therapy. Fourteen of 18 patients 
achieved complete or partial remission with a sustained response of 67% at 1 year. In 
addition, serum albumin increased from a mean of 29 g/L at presentation to 34 g/L at 1 
year (P = 0.001). Importantly, following treatment with rituximab, 6 patients stopped 
prednisolone, 6 patients reduced their maintenance dose and 6 patients remained on the 
same dose (maximum 10 mg). No severe infections were observed. 
The study performed by Tokunaga et al. showed marked improvement following rituximab 
therapy in patients with neuropsychiatric SLE (Tokunaga, Saito et al. 2007). A monoclonal 
antibody was administered at doses of 375 mg/m2 once weekly for four weeks or 1000 mg 
once weekly for two weeks in 10 patients with refractory neuropsychiatric SLE. Treatment 
resulted in rapid improvement of CNS–related manifestations, particularly acute 
confusional state. Rituximab also improved cognitive dysfunction psychosis and seizure and 
reduced the SLEDAI on day 28 in all 10 patients. These effects lasted for more than a year in 
5 patients. In another study, Smith et al. (Smith, Jones et al. 2006) evaluated prospectively 
the effects of rituximab treatment for refractory SLE and vasculitis. Patients received four 
weekly infusions of rituximab at a dose of 375 mg/m2. Intravenous cyclophosphamide (500 
mg) was administered along with the first infusion in an effort to achieve early disease 
control. Remission followeing rapid B cell depletion was achieved in all 11 patients 
including 6 complete responses and 5 partial responses. Moreover, a renal response 
occurred in all 6 patients with lupus nephritis. Clinical improvement was accompanied by a 
significant reduction in the daily dose of prednisone. Seven of 11 patients experienced a 
relapse, a median of 12 months after treatment. After relapse, six patients with SLE were re-
treated with rituximab and all achieved remission and did so more quickly than after the 
primary treatment.  
Rituximab is generally well tolerated. Even fewer adverse events have been observed in 
patients treated for SLE than in the lymphoma patients (Tokunaga, Saito et al. 2007). The 
most common adverse events during or following rituximab therapy are infusion related 
symptoms, typically fever, chills, rigors and hypotension. In patients who receive 
premedication consisting of antipyretic and antihistaminic drugs together with 
corticosteroids, infusion-related side effects are usually only mild or moderate and do not 
require discontinuation of rituximab administration. Occasionally, serious infections were 
also reported. However, these may have been related to the underlying disease and/or 
concomitant therapy with other immunosuppressive agents. In 2006, an FDA alert was 
reported after two SLE patients treated with rituximab had died from progressive multifocal 
leukoencephalopathy (PML) (Ermann and Bermas 2007). However, both patients had 
received additional treatment with cyclophosphamide. At present, it is difficult to estimate 
the risk of this complication in SLE patients treated with rituximab. In recent analysis, 
among the rheumatic diseases, 43 cases of PML (0.44%) were associated with SLE, 24 (0.25%) 
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with rheumatoid arthritis (RA), and 25 (0.26%) with other connective tissue diseases (CTDs) 
(Molloy and Calabrese 2009). Additional controlled studies with new designs are needed to 
define the place of rituximab in the therapeutic arsenal for SLE. 
2.2 New generations of Anti-CD20 monoclonal antibodies 
Over the last few years, new generations of anti-CD20 monoclonal antibodies have been 
developed for potential benefits over the classical, first-generation mAb rituximab. 
Compared with rituximab, new mAbs have enhanced antitumor activity resulting from 
increased CDC and ADCC, and increased Fc binding affinity for the low-affinity variants of 
the FcγRIIIa receptor (CD16) on immune effector cells (Czuczman & Gregory 2010).  
2.2.1 Ofatumumab  
Ofatumumab (HuMax-CD20; Arzerra™, GlaxoSmithKline plc/Genmab A/S) is a second-
generation, fully human, anti-CD20, IgG1 mAb in phase I, II and III trials for hematological 
malignancies and autoimmune diseases such as rheumatoid arthritis (RA) and multiple 
sclerosis. Ofatumumab specifically recognizes an epitope encompassing both the small and 
large extracellular loops of CD20 molecule, and is more effective than rituximab at CDC 
induction and killing target cells. In April 2010, the European Medicines Agency granted a 
conditional marketing authorization for ofatumumab, for the treatment of fludarabine-
refractory CLL patients. It has been reported recently that ofatumumab, administered as 2 
i.v. infusions at doses 300 mg, 700 mg, or 1,000 mg is clinically effective in patients with 
active RA (Østergaard , Baslund et al. 2010). Rapid and sustained peripheral B cell depletion 
was noted in all dose groups. Overall, 70% of patients receiving ofatumumab had a 
moderate or good response according to the European League Against Rheumatism 
(EULAR) criteria at week 24. 
2.2.2 Veltuzumab 
Veltuzumab (IMMU-106, hA20; Immunomedics Inc., Morris Plains, NJ) is a second-
generation, type 1, humanized, anti-CD20, IgG1 mAb with complementarity-determining 
regions (CDRs) similar to rituximab (Goldenberg, Rossi et al. 2009). This mAb is generated 
using the same human immunoglobulin as epratuzumab and has a >90% humanized 
framework. It is also very similar to rituximab in terms of antigen binding, specificity 
binding, and dissociation constant. Veltuzumab differs from rituximab by one amino acid 
(Asp101 instead of Asn101) in the CDR 3 of the variable heavy chain. Smaller murine 
regions may reduce infusion reactions, infusion times, and immunogenicity. This antibody 
has enhanced binding avidities and a stronger effect on CDC compared with rituximab in 
selected cell lines. Veltuzumab is safe and active agent in NHL. B cells were depleted after 
the first infusion of all tested doses, including dose levels less than those typically used with 
rituximab (Morschhauser, Leonard et al. 2009).  
2.2.3 Ocrelizumab  
Ocrelizumab (Genentech Inc/Biogen Idec Inc/Chugai Pharmaceutical Co Ltd/Roche 
Holding Ag) is a second-generation, type 1, humanized, anti-CD20, IgG1 mAb with 
modifications of the Fc region that lead to enhanced ADCC and reduced CDC activities 
compared with rituximab (Kausar, Mustafa et al. 2009).This agent has the potential for 
enhanced efficacy compared with rituximab due to increased binding affinity for the low-
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affinity variants of the FcγRIIIa receptor on immune effector cells (Genovese, Kaine et al. 
2008). Ocrelizumab binds to a different, but overlapping, epitope of the extracellular domain 
of CD20 as compared with rituximab. Ocrelizumab is a humanized mAb with the potential 
for enhanced efficacy in lymphoid malignancies compared with rituximab due to increased 
binding affinity for the low-affinity variants of the FcγRIIIa receptor (Faria & Isenberg 2010). 
2.2.4 GA-101  
GA-101 (RO5072759) is a fully humanized, type II, IgG1 mAb derived from humanization of 
the parental B-Ly1 mouse antibody and subsequent glycoengineering using GlycoMab® 
technology. GA-101 was designed for enhanced ADCC and superior direct cell-killing 
properties, in comparison with currently available type I antibodies (Robak 2009). In 
contrast to rituximab GA101, mediated significant NK cell degranulation in whole blood 
samples. Thus, CDC and ADCC are believed to be the major effector mechanisms of GA101 
in whole blood assays (Bologna, Gotti et al. 2011).  
2.2.5 TRU-015 
TRU-015 (CytoxB20G, Trubion Pharmaceuticals Inc and Pfizer Inc) is a small modular 
immunopharmaceutical (SMIP) derived from key domains of an anti-CD20 antibody. TRU-
015 represents a novel biological compound that retains Fc-mediated effector functions and 
is smaller than mAbs (Rubbert-Roth 2010). SMIPs belong to a novel proprietary biologic 
compound class that retain Fc-mediated effector functions and are smaller than mAbs 
(Robak, Robak et al. 2009). A SMIP molecule is a single-chain polypeptide consisting of one 
binding domain, one hinge domain, and one effector domain. The TRU-015 SMIP molecule 
is the homogeneous single-chain immunotherapeutic derived from key domains of an anti-
CD20 antibody, for the potential intravenous infusion treatment of RA, SLE and B-cell 
lymphoid malignancies (Hayden-Ledbetter, Cerveny et al. 2009). This molecule is a compact 
dimer of 104 kDa that co-migrates with albumin in size exclusion chromatography and 
retains a long half-life in vivo. It is effective in mediating target cell killing in the mechanism 
of ADCC but has reduced CDC activity compared with rituximab. TRU-015 could represent 
a novel therapy for the treatment of SLE, although the efficacy, safety profile, and 
advantages of this compound compared with existing therapeutic options would need to be 
established in clinical trials (Burge, Bookbinder et al. 2008). TRU-015 has shown clinical 
efficacy and tolerability in phase IIa and IIb studies in patients with rheumatoid arthritis, 
and clinical development efforts for the treatment of lymphoma and inflammatory disease 
are ongoing. In the ongoing trial pharmacokinetics of TRU-015 after a single administration 
in subjects with membranous nephropathy secondary SLE is investigated (ClinicalTrials.gov 
Identifier: NCT00479622). 
All new anti-CD20 mAbs are potentially useful in the treatment of SLE. However, the 
advantage of these new drugs over rituximab should be proven by well-designed clinical 
trials in rituximab-refractory patients or through head-to-head comparison.  
3. Other B cell targeting monoclonal antibodies 
3.1 Anti-CD22 antibody epratuzumab 
Epratuzumab (Immunomedics, Inc.) is a humanized monoclonal IgG antibody that 
specifically targets the CD22 antigen on B cells (Leonard & Goldenberg 2007). This 
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monoclonal antibody is 90% to 95% of human origin thus greatly reducing the potential for 
immunogenicity. Unconjugated anti-CD22 antibodies only partially deplete B cells, but 
might deliver a negative signal by binding CD22 to the cell surface (Daridon, Blassfeld et al. 
2010). Treatment of SLE patients with epratuzumab leads to a reduction of circulating CD27 
negative B-cells, although epratuzumab is weakly cytotoxic to B-cells in vitro. Epratuzumab 
binding was higher on B-cells relative to T-cells. In addition, weak non-specific binding of 
epratuzumab on monocytes was noted. On B-cells, binding of epratuzumab was enhanced 
on CD27negative B-cells compared to CD27 positive B-cells, primarily related to a higher 
expression of CD22 on CD27negative B-cells. Epratuzumab also enhanced the migration of 
CD27negative B-cells towards the chemokine CXCL12. 
Recently, Dorner et al. reported the results of an open-label, single-center study of 14 
patients with moderately active SLE (Dörner, Kaufmann et al. 2006). Patients received 360 
mg/m2 of epratuzumab intravenously every 2 weeks for 4 doses with analgesic 
antihistamine premedication prior to each dose. Total BILAG scores decreased by 50% in 
all 14 patients at some point during the study with 92% having decrease in various amounts 
continuing to at least 18 weeks. 
Epratuzumab toxicity consisted primarily of mild to moderate transient infusion–related 
events during the first infusion. These results support conducting multicenter controlled 
studies to examine the effects of epratuzumab in broader patient populations. A U.S. patent 
has been issued to Immunomedics, Inc. for epratuzumab as a potential new treatment for 
lupus. 
3.2 Anti-BlyS monoclonal antibodies 
The B-lymphocyte Stimulator (BLyS) and A Proliferatiave Inducing Ligand (APRIL) are 
ligands for receptors BAFF-R (B Cell Activation Factor), BCMA (B Cell Maturation 
Associate) and TACI (Transmembrane Activator and Calcium Reproducing Initiator). BLyS 
also known as BAFF, THANK, TALL-1 or zTNF4, is a member of TNF super-family, which 
stimulates immunoglobulin (Ig) production by binding to specific receptors (King and Hahn 
2007). In patients with SLE, the serum levels of BLyS are elevated and its neutralization has 
suggested that higher levels of BLyS contribute to the generation of autoantibodies and is 
important in SLE pathogenesis (Toubi, Kessel et al. 2006). In consequence, neutralization of 
BLyS may play a role in the therapy of this disease. 
3.2.1 Belimumab 
Belimumab (Human Genome Sciences, (Rockville, MD, USA)/Glaxo Smith Kline, 
(Uxbridge, UK)) is a fully human IgG1 mAb that specifically binds and inhibits the 
biological activity of BLyS (Wiglesworth, Ennis et al. 2010). The antibody exerts its biological 
activity by preventing the binding of BLyS to its receptors, resulting in autoreactive B cell 
apoptosis (Baker, Edwards et al. 2003). It also inhibits soluble BLyS activity at subnanomolar 
concentrations in a murine model. Belimumab inhibits also BLyS- induced proliferation of 
B-cells in vitro and prevents human BLyS-induced increases in splenic B-cell numbers and 
serum IgA titers in mice. 
The safety, tolerability, immunogenicity, and pharmacology of belimumab were 
investigated in a phase I, randomized, placebo controlled, double-blind study in patients 
with SLE (Furie, Stohl et al. 2008). Seventy patients with mild to moderate disease were 
enrolled in this trial. Fifty-seven patients were treated with mAb and 13 with placebo. The 
drug was administered at 4 different doses (1.0, 4.0, 10 and 20 mg/kg) as single infusions, 21 
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days apart. The incidence of adverse events and laboratory abnormalities was similar 
among the belimumab and placebo groups. A significant reduction in the median 
percentage of CD20+ B-cells was noted with a one and two doses of belimumab versus 
placebo. However, SLE activity did not change after treatment with this mAb. 
Wallace et al. assessed the safety, tolerability, biological activity, and efficacy of belimumab in 
combination with standard of care therapy in patients with active SLE (Wallace, Stohl et al. 
2009). In this phase II, randomized trial 449 patients with SELENA-SLEDAI score ≥ 4 were 
randomly assigned to belimumab (1, 4, 10 mg/kg) or placebo in a 52-week study. In this study, 
belimumab treatment did not result in significant improvement compared with placebo. 
Percentage change in the SELENA-SLEDAI score at week 24, the primary endpoint of the 
study, was similar in both arms (19.5% in the belimumab group versus 17.2% in the placebo 
group). There was no significant difference in time to first SFI-defined flare over 52 weeks 
between the belimumab and placebo groups (67 versus 83 days, respectively). However, the 
median time to first SLE flare during weeks 24–52 was significantly longer with belimumab 
treatment (154 versus 108 days; P=0.0361). During the 52-week study and 8-week follow-up 
period, the incidence of AEs were similar in all treatment groups, including placebo. Only 
urticaria was statistically more frequent in belimumab-treated patients (4% versus 0%). 
The efficacy and safety of belimumab in patients with active SLE was also assessed in a 
large, randomized, multicenter study recently reported by Navarra et al 2011 (Navarra, 
Guzmán et al. 2011). In this trial, 865 patients with scores of at least 6 on the Safety of 
Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus 
Disease Activity Index (SELENA-SLEDAI) were randomly assigned to belimumab 1 mg/kg 
or 10 mg/kg, or placebo by intravenous infusion in 1 h on days 0, 14, and 28, and then every 
28 days until 48 weeks, with standard of care. Significantly higher Systemic Lupus 
Erythematosus Responder Index (SRI) rates were noted with belimumab 1 mg/kg (51%, 
P=0.0129) and 10 mg/kg (58%, p=0.006) than with placebo (44%) at week 52. In addition, 
more patients had SELENA-SLEDAI score reduced by at least 4 points during 52 weeks with 
belimumab 1 mg/kg (53%, P=0.0189) and 10 mg/kg (58%, P=0.0024) than with placebo 
(46%). Moreover, more patients receiving belimumab 1 mg/kg (78%, P=0.1064) and 10 
mg/kg (81%, P=0.0181) had no new BILAG A or no more than 1 new B flare than did those 
receiving placebo (73%). There was no difference in rates of adverse events in patients given 
belimumab 1 mg/kg and 10 mg/kg, and placebo. Serious infection was noted in 8%, 4%, 
and 6% patients, respectively. Severe or serious hypersensitivity reactions on an infusion 
day were reported in four patients.  
3.2.2 LY2127399 
Anti-BAFF monoclonal antibody LY2127399 (Eli Lilly & Company Limited) is a fully human 
IgG4 antibody with neutralizing activity against both membrane-bound and soluble BAFF. 
This may reduce the activity, proliferation and survival of B-cells. The ongoing study 
evaluates the efficacy, safety and tolerability of two different doses of LY2127399 
administered in addition to standard of care therapy in patients with active SLE 
(ClinicalTrials.gov Identifier: NCT01205438). 
4. Monoclonal antibodies inhibiting T cell costimulation 
Cytotoxic lymphocyte-associated antigen-4 (CTLA-4) is a potent inhibitor of the costimulation 
pathway necessary to activate T cells. Abatacept (CTLA-4 immunoglobulin; CTLA4-Ig, 
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Orencia) is a recombinant fully humanized fusion protein, composed of the extracellular 
domain of human CTLA-4 and a modified Fc part of IgG-1that was engineered to prevent 
complement fixation (St Clair 2009). It targets T cell activation by interfering with one of the 
costimulatory mechanisms that are essential for cell activation. CTLA4-Ig binds to B7-1 and 
B7-2 on antigen presenting cells and downregulates T cell activation by disrupting CD28-B7 
costimulatory interaction. Abatacept blocks the interaction between CD28 expressed on the 
surface of T cells and CD80/CD86 on the surface of antigen-presenting cells. The drug was 
approved for RA by the FDA US (Food and Drug Administration) in 2005. Abatacept was 
compared to placebo in a randomized, placebo controlled, phase II trial of patients with active 
SLE characterized by arthritis, serositis, or rash (Merrill, Burgos-Vargas et al. 2010). SLE 
patients were randomized at a ratio of 2:1 to receive abatacept (10 mg/kg of body weight) or 
placebo. Prednisone (30 mg/day or equivalent) was given for 1 month, and then the dosage 
was tapered. There was no difference in the percentage of patients who experienced the 
primary endpoint of SLE flare, as defined by BILAG, over the course of 52 weeks. However, 
the investigators discerned a difference in flare rates between the abatacept group (64%) and 
placebo group (83%). This difference was especially pronounced in the subgroup of patients 
with arthritis. The frequency of adverse events was comparable in the abatacept and placebo 
groups (90.9% versus 91.5%), but serious adverse events were higher in the abatacept group 
(19.8 versus 6.8%). Most serious adverse events were single, disease-related events occurring 
during the first 6 months. Improvements in certain exploratory measures suggest that 
abatacept has some efficacy in patients with non-life-threatening manifestations of SLE.  
5. Anticytokine monoclonal antibodies 
In the course of SLE, a wide variety of cytokines is dysregulated, many of which are likely to 
influence autoimmunity and lupus tissue inflammation (La Cava. 2010; Robak, Kulczycka et 
al. 2007). They are not only involved in the immune dysregulation of SLE, but also in the 
local inflammatory response which ultimately leads to tissue injury. Proinflammatory 
cytokines such as tumor necrosis factor  (TNF), iterleukin-6 (IL-6), IL-1 and interferon- 
(IFN-) may play an important role in propagating the inflammatory process responsible for 
tissue damage. IL-12, IL-15 and IL-18 are probably also involved in pathogenesis of SLE. The 
possibility of blocking the proinflammatory cascade by selective inactivation of cytokines 
can be a successful therapy for patients with SLE. 
5.1 Anti-IL-6 monoclonal antibodies 
Data from several studies suggests that IL-6 plays an important role in the B-cell 
hyperactivity and immunopathology of SLE (Klashman, Martin et al. 1991). One of the most 
important effects of IL-6 is to induce the maturation of B lymphocytes into plasma cells and 
augment the imunoglobulin secretion. IL-6 binds to the IL-6 receptors which belong to the 
type 1 cytokine receptor superfamily that consists of two subunits, namely the IL-6 R and 
the gp 130. This cytokine may have a direct influence in mediating tissue damage. Elevated 
levels of IL-6 were detected in the serum, urine and renal glomerulli of patients with active 
SLE and in murine models of SLE (Grondal, Gunnarsson et al. 2000).  
Tocilizumab (ACTEMRA, MRA, Roche Pharmaceuticals) is a humanized anti-human IL-6R 
mAb considered as a therapeutic option for patients with SLE. It is an antibody which 
inhibits the interleukin-6 receptor. It binds to both soluble IL-6R and transmembrane IL-6R 
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and inhibit IL-6 binding to its receptors, leading to the blockade of IL-6 signaling through 
both receptors (Jones and Ding 2010). Tocilizumab suppresses the biological activity of IL-6 
and is now being used in clinical trials for RA and SLE (ClinicalTrials.gov Identifier: 
NCT00046774). An intraperitoneal administration of an anti-IL-6 mAb decreased the 
production of anti-ds DNA antibodiess in murine model of SLE and prevented the 
development of severe kidney disease. These results suggest that treatment with anti-IL-6 
mAb has a beneficial effect on autoimmunity in murine SLE and that autoreactive B cells 
may be the primary target for anti-IL-6 antibody treatment (Liang, Gardner et al. 2006). 
Tocilizumab is an effective agent in all the stages of RA (Jones, Sebba et al. 2010). Tocilizumab 
is the first agent that has been shown to be superior to methotrexate (MTX) as monotherapy 
for the signs and symptoms of this disease. It is also an active drug in SLE patients. 
Tocilizumab when used in mild to moderate lupus patient has demonstrated preliminary 
success and good tolerability in an open-label phase I dosage-escalation study (Illei, Shirota et 
al. 2010). In this trial 16 patients with mild-to-moderate disease activity were assigned to 
receive 1 of 3 doses of tocilizumab given intravenously every other week for total of 7 
infusions: 2 mg/kg in 4 patients, 4 mg/kg in 6 patients, or 8 mg/kg in 6 patients. Patients were 
then monitored for an additional 8 weeks. The median decrease in anti-dsDNA antibody levels 
at week 14 was −9 IU/ml (P = 0.03). There was improvement in overall disease activity over 
the course of treatment. Mean SLAM scores decreased from 7.1 at baseline to 5.0 at week 14 (P 
= 0.002), and mean mSELENA–SLEDAI scores decreased from 9.5 to 5.5 (P = 0.001). In 
addition, there was no SLE flare during the treatment period. The infusions were well 
tolerated, without any clinically significant infusion reactions. However, the treatment 
induced dosage-related decreases in the absolute neutrophil count, with a median decrease of 
38% in the 4 mg/kg dosage group and 56% in the 8 mg/kg dosage group. Infections were 
observed in 11 patients between the start of study treatment and the end of the follow up 
period. This study provides the first evidence that treatment with tocilizumab has an 
acceptable safety profile and suggests a possible immunologic and clinical benefit in SLE. 
5.2 Anti-IL 10 monoclonal antibody  
Interleukin-10 (IL-10) is a cytokine produced mainly by monocytes and lymphocytes. It 
impedes the activation of antigen presenting cells, down-regulates the expression of co-
stimulatory molecules and blunts T cell activation and TNF-α secretion. IL-10 boosts B cell 
proliferation and immunoglobulin class switching resulting in enhanced antibody secretion 
with the capacity to enter extravascular compartments and promote inflammation in SLE (Yap 
& Lai 2010). The levels of IL-10 increase in the serum of patients with active SLE and correlates 
with disease activity. Alteration in IL-10 regulation may result in accelerated T-cell apoptosis 
and aberrant T-cell dependent B-cell function. In animal models of lupus nephritis, anti-IL 10 
blockade offered some benefits in limiting renal damage (Ravirajan, Wang et al. 2004). The 
beneficial effect of a combined therapy using both anti-IL-10 and anti-C5 mAb to prevent or 
reduce the effect of the humoral immune response in lupus disease was also suggested. 
Preliminary data has shown that anti-IL-10 monoclonal antibody improved cutaneous lesions, 
joint symptoms, and SLEDAI in lupus patients (Llorente, Richaud-Patin et al. 2000). The anti-
IL-10 monoclonal antibody was administered to six patients with steroid resistant SLE in an 
open label pilot study. Treatment consisted of an 20 mg/day intravenous administration of an 
anti-IL-10 murine mAb (B-N10) for 21 consecutive days, with a follow-up period of 6 months. 
Therapy was well tolerated and marked improvement in skin lesions and joint symptoms was 
observed in all patients over the next 6 months. Furthermore, three times lower doses of 
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prednisone were used. The study indicates that the use of IL-10 antagonists may be beneficial 
in the management of refractory SLE. 
6. Anti-CD40 and anti-CD40L monoclonal antibodies 
CD40, a member of the tumor necrosis factor receptor super family, is highly expressed in 
normal B-cells and a variety of B-cell malignancies. CD40 ligand, also called CD154 or gp39, 
is a protein expressed on activated CD4+ T cells as well as on platelets, mast cells, 
macrophages, basophils, NK cells and B lymphocytes. An increased expression of CD40L 
has been found in the peripheral lymphocytes of patients with active SLE (Devi, Van 
Noordin et al. 1998). Moreover, serum levels of CD154 (CD40L) are higher in lupus patients 
than in normal persons (van Kooten & Banchereau 2000). The high expression of CD154 on 
T and B cells may increase production of potentially harmful auto-antibodies. The results of 
preclinical studies indicate that lupus-prone mice treated with anti-CD40L Abs had 
diminished inflammation, reduced anti-DNA autoantibody production and prolonged 
survival. Prolonged administration was particularly helpful in preventing fibrosis in 
severely nephritic mice (Kalled, Cutler et al. 2001). These results prompted the testing of 
anti-CD40L mAbs in human SLE.  
6.1 Anti-CD40 monoclonal antibodies 
Two mAbs directed against CD40 have been developed and investigated in preclinical 
studies and clinical trials, lucatumumab (HCD122) and dacetuzumab (SGN-40) (Kelley, 
Gelzleichter et al. 2006).  
6.1.1 Lucatumumab 
Lucatumumab ((HCD122, CHIR-0.12.12; Novartis Pharmaceuticals) is a fully human anti-
CD40 mAb directed against the B-cell surface antigen CD40. It blocks CD40/CD40L 
interactions in vitro and inhibits CD40L-induced proliferation of human peripheral blood 
lymphocytes without disturbing baseline lymphocyte proliferation. Lucatumumab triggers 
cell lysis via ADCC in cells overexpressing CD40 (Luqman, Klabunde et al. 2008). 
6.1.2 Dacetuzumab  
Dacetuzumab (Seattle Genetics, Inc), is another humanized anti-CD40 IgG1 mAb, which 
induces ADCC and apoptosis of normal and malignant B-cells (Kelley, Gelzleichter et al. 
2006). Dacetuzumab is able to initiate multiple signalling cascades upon ligation of CD40 on 
NHL cell lines. Dacetuzumab-mediated cytotoxicity is associated with up-regulation of 
cytotoxic ligands of the tumor necrosis factor (TNF) family including Fas/FasL, TNF-related 
apoptosis-inducing ligand, and TNFalpha. 
6.2 Anti-CD40L monoclonal antibodies 
6.2.1 IDEC-131 
IDEC-131/E6040 (Idec Pharmaceuticals Corp. San Diego) is a humanized mAb against 
human CD154, comprising human 1 heavy chains and human  light chains with 
complementarity-determining regions of murine mAb clone 24-31. In Phase I clinical trial, 
IDEC-131 was administered in a single intravenous infusion at doses of 0.05-15.0 mg/kg in 
patients with SLE. Patients were followed for 3 months to evaluate toxicity and 
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pharmacokinetics (Davis, Totoritis et al. 2001). All patients experienced at least one adverse 
event. However, no infusion related cytokine-release syndrome was observed and all 
patients completed treatment. In a phase II, double blind, placebo-controlled, multiple-
center, multiple-dose study, 85 patients with mild-to-moderately active SLE were 
randomized to receive 6 infusions of IDEC-131, ranging from 2.5 mg/kg to 10.0 mg/kg, or 
placebo over 16 weeks (Kalunian, Davis et al. 2002). At week 20, the mean change from 
baseline total SLEDAI scores indicated improvement in disease activity within each 
treatment group. In addition, the median global BILAG scores at week 20 indicated a 
reduction in SLE activity. However, results did not differ among the IDEC-131 treatment 
and placebo groups, and no dose-response relationship was noted at week 20. Moreover, the 
changes in levels of anti-dsDNA antibody and serum complement were not statistically 
significant in any group or between treatment groups and placebo. In addition, the changes 
in levels of anti-dsDNA antibody and serum complement were not different between 
treatment groups and placebo. The adverse events were also similar between the IDEC-131 
and placebo groups. 
6.2.2 BG9588 
BG9588 (Biogen, Inc., Cambridge, MA) is a recombinant humanized anti-human CD40L 
monoclonal antibody that specifically binds to the CD40 ligand expressed on the surface of 
activated T lymphocytes. It blocks the CD40L/CD40 interaction between T and B cells that is 
required for the initiation for certain antibody responses. A short course of BG9588 
treatment in patients with proliferative lupus nephritis reduced anti-dsDNA antibodies, 
increased C3 concentrations, and decreased hematuria (Boumpas, Furie et al. 2003). These 
results indicate that the drug has immunomodulatory action. Additional studies will be 
needed to evaluate its long-term effects. 
7. Anticomplement antibody 
Patients with SLE have widespread activation and deposition of the complement fragment 
in affected tissues. In murine models of SLE, the administration of the anti-C5 monoclonal 
antibody delayed the onset of proteinuria and prolonged survival. Moreover, 
pharmacological blockade of C5 receptor with a specific receptor antagonist reduces disease 
manifestation in experimental lupus nephritis (Cordeiro & Isenberg 2008). Furthermore, in 
mice with renal disease induced by a human anti-dsDNA antibody, RH-14 anti-C5 
monoclonal antibody significantly reduced proteinuria.  
Eculizumab (Soliris; Alexion Pharmaceuticals, Inc., Cheshire, CT) is a recombinant 
humanized monoclonal antibody that works by binding to complement protein C5, 
inhibiting its enzymatic cleavage, blocking formation of the terminal complement complex, 
and thus preventing red cell lysis (Parker , Kar et al. 2007). It has a molecular weight of 148 
kD. Eculizumab is approved for the treatment of paroxysmal nocturnal hemoglobinuria 
(PNH) (Hillmen, Young et al. 2006). This antibody is potentially useful for treating patients 
with lupus nephritis. In this disease, the terminal components of the complement C5b-C9 
play an important role in mediating the inflammation and the damage of podocytes and 
glomerular basement membrane (Robak & Robak 2009). Eculizumab has been recently 
developed and investigated in a phase I single dose study in SLE. 
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MoAb Target Antibody characteristics 
Rituximab CD20 Type I, 1st generation IgG1-, mAb, containing murine 
light– and heavy–chain variable–region sequences and 
human constant region sequences
Ocrelizumab CD20 Type I, 2nd generation, humanized fusion IgG1,  
binding to different CD20 epitope than rituximab, 
enhanced ADCC, reduced CDC, enhanced affinity for 
FcγRIIIa RIIIa 
Veltuzumab 
(IMMU-106, hA20) CD20 
Type I, 2nd generation, humanized IgG1, binding to 
different CD20 epitope than rituximab, enhanced ADCC, 
reduced CDC, enhanced affinity for FcγRIIIa RIIIa 
Ofatumumab 
(HuMax-CD20, 
(Arzerra) 
CD20 
Type I, 2nd generation, Human IgG1, binding to different 
CD20 epitope, more effective at CDC than rituximab 
GA-101 
(RO5072759) 
CD20 Type II, 3rdgeneration, humanized IgG1, superior  
ADCC than rituximab and superior direct cell-killing 
ability
AME-133v 
(LY2469298) 
CD20 Type I, 3rd generation, humanized fusion IgG1, enhanced 
affinity for FcγRIIIa, superior ADCC
PRO131921 CD20 Type I, 3rd generation, humanized fusion IgG1, improved 
binding to FcγRIIIa, better ADCC, superior anti-tumor 
efficacy
TRU-015 CD20 SMIP derived humanized fusion protein, ADCC and 
apoptosis induction
Epratuzumab 
(hLL2) 
CD22 Humanized IgG1-, , 90% to 95% of human origin , acting as 
an immunomodulatory agent, stimulating the CD22 
molecule
Belimumab BLyS Fully human IgG1 mAb that specifically binds and inhibits 
the biological activity of BLyS
Abatacept B7-1 and 
B7-2  
Recombinant fully humanized fusion protein, composed 
of the Extracellular domain of human CTLA-4 and a 
modified Fc part of IgG1
Tocilizumab 
(ACTEMRA, MRA)
IL-6R Recombinant, humanised monoclonal IgG1 antihuman 
interleukin 6-receptor antibody
IDEC-131 CD40L IDEC-131/E6040, humanized mAb against human CD154, 
comprising human 1 heavy chains and human  light 
chains with complementarity-determining regions of 
murine mAb clone 24-31
BG9588 CD40L Recombinant humanized anti-human CD40L mAb 
consists of the complementarity-determining regions of 
the murine monoclonal antibody 5c8 (anti-human CD40L 
antibody) with human variable-region framework 
residues and IgG1 constant region 
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MoAb Target Antibody characteristics 
Lucatumumab 
(HCD122, CHIR-
0.12.12) 
CD40 Human IgG1 mAb that blocks CD40/CD40L interactions 
and inducesADCC 
Dacetuzumab (SGN-
40) 
CD40 Humanized anti-CD40 IgG1 mAb, which induces ADCC 
and apoptosis of B-cells
Eculizumab Comple
mentpro-
tein C5
Recombinant humanized mAb binding to complement 
protein C5, inhibiting its enzymatic cleavage, blocking 
formation of the terminal complement complex 
ADCC=antibody-dependent cellular cytotoxicity; BLyS=B-lymphocyte Stimulator;  
CDC=complement-dependent cytotoxicity; mAb= monoclonal antibody;  
SMIP=small modular immunopharmaceutical 
Table 1. Monoclonal antibodies potentially useful in systemic lupus erythematosus 
8. Conclusions 
In recent years, clinical studies have been undertaken with selected mAbs in the treatment 
of SLE. The most frequently used mAb is rituximab, which is directed against CD20, a 
membrane protein expressed on B lymphocytes. Rituximab is effective in depleting B cells 
from peripheral blood, lymph nodes and bone marrow. Recent clinical studies confirm the 
high activity of rituximab in SLE patients, especially with lupus nephritis and 
neuropsychiatric involvement. Rituximab was generally well tolerated. However, 
occasionaly serious infections were reported. Over the last few years new generations of 
anti-CD20 mAbs have been developed for potential benefits over rituximab. They were 
engineered to have augmented antitumor activity by increasing CDC or ADCC activity and 
increased Fc binding affinity for the low-affinity variants of the FcγRIIIa receptor (CD16) on 
immune effector cells. This mAbs are are highly cytotoxic against B-cell lymphoid cells and 
are now being evaluated in clinical trials.  
More recently, several newer mAbs have been developed and are being evaluated in phase 
I/II clinical trials. These include anti-cytokine therapies anti-CD40L mAbs, anti-CD-22 mAb, 
anti-BLys mAbs and anti- C5 mAbs. Belimumab is a fully human monoclonal antibody that 
binds to BLyS and inhibits its biological activity. Significantly positive results in both phase 
3 studies have raised hopes that belimumab may be the long-awaited new effective therapy 
for SLE. Proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin- 6 
(IL-6) play an important role in propagating the inflammatory process responsible for tissue 
damage. Blocking of these cytokines by mAbs can be also a successful therapy for patients 
with SLE. Finally, mAb eculizumab that specifically inhibits terminal complement activation 
has been recently developed and investigated in a phase I single dose study in SLE. These 
potentially useful agents should be further evaluated in well designed controlled trials.  
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